Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY), which twenty-one different brokerages are currently following, has been given an average rating of “Moderate Buy” by these brokerages, as reported by Bloomberg. This rating indicates that these brokerages believe the stock will likely increase in price over the next few months. A total of twelve industry professionals have advocated for the purchase of the stock, while seven have simply recommended keeping it in one’s portfolio. Recent coverage of the stock by brokerage firms indicates that these firms have an average one-year price goal of $235.83 for the stock. This information is derived from the recent coverage of the stock.
There have been a few different brokerages that have provided their perspectives on ALNY. Oppenheimer increased their price objective on Alnylam Pharmaceuticals from $170.00 to $256.00 and categorized the stock as “outperform” in a research report published on Friday, September 9. In a report made public on November 2, Wainwright lowered its “buy” rating and price objective for Alnylam Pharmaceuticals shares, moving them from $430.00 to $415.00. This was done in response to a decrease in the stock price. JPMorgan Chase & Co. lowered their target price for Alnylam Pharmaceuticals from $204.00 to $200.00 and gave the company a “neutral” rating in a report made public on Monday, October 24. The price objective for Alnylam Pharmaceuticals was reduced from $240.00 to $236.00 in a research report made public by Barclays on Friday, October 28. The brokerage firm also gave the company’s stock an “overweight” rating. SVB Leerink increased their price objective on Alnylam Pharmaceuticals from $140.00 to $145.00 and upgraded the company’s rating from “market perform” to “outperform” in a research note published on Monday, November 7.
When trading started on Friday morning, the price of an individual share of ALNY was $236.92. The current price of Alnylam Pharmaceuticals is $242.32, which is higher than the one-year high of $117.58 but lower than the one-year low of $242.32. There is a debt-to-equity ratio of 3.85, a current ratio of 3.48, and a quick ratio of 3.33. All three ratios are identical. The stock’s 50-day moving average and 200-day moving average are both at their respective current levels of $210.38 and $188.99. The company possesses a price-to-earnings ratio of -24.25, a beta value of 0.54, and a market capitalization of $29.15 billion.
Alnylam Pharmaceuticals (NASDAQ: ALNY) published its report on the company’s performance during the third quarter on Thursday, October 27. The report was available online. The earnings per share that the biopharmaceutical industry reported for the quarter were $3.32, which is $0.46 lower than the consensus estimate of $1.86. Alnylam Pharmaceuticals reportedly had a negative return on equity of 430.74% and a negative net margin of 123.02%, as stated in their respective reports. The company reported a revenue of $264.31 million for the quarter, which is significantly lower than the consensus expectation of $291.81 million for the quarter’s revenue. The company incurred a loss of $1.72 per share during the same period the year before. Compared to the same quarter of the previous year, the rise in revenue was 40.9% higher than the previous quarter’s total. Alnylam Pharmaceuticals is expected to have earnings of $9.66 per share in 2018, according to projections made by sell-side analysts.
Important shareholders have been known to adjust the percentage of the company’s stock they own throughout the past few months. Through the acquisition of shares of Alnylam Pharmaceuticals during the third quarter, Guardian Wealth Advisors LLC established a brand-new position with a value of $27,000. Allworth Financial LP saw a rise of 708.7% during the third quarter in the amount of Alnylam Pharmaceuticals stock that it owned as a percentage of the company’s total assets. Allworth Financial LP now has 186 shares of the biopharmaceutical company’s stock, which is currently valued at $37,000 after purchasing an additional 163 shares during the period. These shares were acquired through the purchase of additional shares during the period. During the second quarter, SeaCrest Wealth Management LLC spent approximately $44,000 to purchase an additional stake in Alnylam Pharmaceuticals. Schroders, Inc. increased its holdings in Alnylam Pharmaceuticals during the year’s second quarter at a total cost of approximately 74,000 dollars for the new position. CI Investments Inc., not to be outdone, during the third quarter of this year, increased the amount of Alnylam Pharmaceuticals stock that is owned by 52.7%. CI Investments Inc. now holds 394 shares of the biopharmaceutical company’s stock, valued at $79,000 after the company made an additional purchase of 136 shares during the period in question. During the period in question, these shares were purchased. Institutional investors and hedge funds collectively own 93.21% of the total number of shares of the company, making them the company’s largest stockholders.
In the industry of biopharmaceuticals, there is a company named Alnylam Pharmaceuticals, Inc. that focuses on the research, development, and marketing of cutting-edge treatments that are predicated on the interference of ribonucleic acid. This treatment
Discussion about this post